NeuroVive clarifies strategy for NeuroSTAT
(WorldNews Finland)

NeuroVive Pharmaceutical AB Company Announcement NeuroVive clarifies strategy for NeuroSTAT NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) today announced that it intends to initiate a process with the aim to transfer the rights to develop and commercialize its NeuroSTAT program into a new company based in the US. The effort is in line with NeuroVive`s strategy to focus its resources on its primary mitochondrial disease (PMD) projects, KL1333 and NV354. The process will start immediately with the plan to, subject to funding, establish the new company (NewCo) during the second half of 2020. The plan to transfer the NeuroSTAT assets to NewCo is a further step towards focusing the company...